NASDAQ$AKBA
Akebia Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter and highlighted recent business activities.
Akebia Therapeutics reported total revenues of $37.4 million for the third quarter of 2024, compared to $42.0 million for the third quarter of 2023. The net loss for the quarter was $20.0 million, compared to a net loss of $14.5 million for the same period in the previous year. The company is preparing for the U.S. market availability of Vafseo expected in January 2025.
- Vafseo on track for U.S. market availability expected in January 2025.
- Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo.
- Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code.
- Akebia partnered with U.S. Renal Care (USRC) to initiate a collaborative trial evaluating mortality and hospitalization outcomes for dialysis patients taking Vafseo.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$37.4M
Revenue by segment
Akebia · $40.1M total across 2 segments · Q1 2023
- Auryxia$34.8M-15.9%86.8%
- License & other revenue$5.3M-73.8%13.2%
Forward guidance
Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years.
Tailwinds
- Vafseo on track for U.S. market availability expected in January 2025.
- Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo.
- Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code.
- Akebia partnered with U.S. Renal Care (USRC) to initiate a collaborative trial evaluating mortality and hospitalization outcomes for dialysis patients taking Vafseo.
- Existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch, for at least two years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro